AARP Hearing Center
Even as delta continues to plow a path of destruction across the U.S., health experts are keeping a close eye on a new variant, called mu. While its presence pales in comparison to delta’s — mu makes up roughly 0.5 percent of COVID-19 cases in the U.S., while delta accounts for about 99 percent — “it certainly has some features that are concerning,” says John O’Horo, M.D., a critical care and infectious disease specialist at Mayo Clinic.
Here’s what we know so far about the mu variant:
1. Experts say mu isn’t an immediate threat
Viruses are constantly changing and evolving, and once one develops one or more mutations, it becomes a variant. Several coronavirus variants have surfaced since the start of the pandemic, and mu is one of the latest.
It was first detected in Colombia in January, and has since spread across the globe, including to the U.S., where more than 2,000 cases have been recorded, according to the COVID-19 tracking site Global Initiative on Sharing All Influenza Data (GISAID).
Mu still ranks lower than delta on the World Health Organization’s “threat board,” as O’Horo calls it — it’s considered a “variant of interest,” while delta is classified a “variant of concern.” And it hasn’t been listed under either label by the Centers for Disease Control and Prevention (CDC) — but that could change.
“We’re paying attention to it,” Anthony Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases, said in a recent coronavirus task force briefing. “We take everything like that seriously, but we don’t consider it an immediate threat right now.”
2. Mu’s mutations could become problematic
The reason researchers are keeping a close eye on mu is because it has “a constellation of mutations” that suggest it could cause some trouble for COVID-19 vaccines and treatments, Fauci noted during the briefing. And some of these viral mutations are around the spike protein — a feature that allows the coronavirus to enter the cells in the body and cause an infection, O’Horo explains.
Here’s why that could be a problem: The vaccines train the body to recognize this spike protein and prompt the immune system to produce antibodies to fight it. A few of the drugs authorized to treat COVID-19, known as monoclonal antibodies, work in a similar way: They bind to the spike protein and help to prevent the virus from invading the cells. Any mutations in the spike protein could affect the ability of the antibodies to do their job.